Francais | Home | Contact us
Rank Ligand
  • RANK L in
    Healthy Bone
  • RANK L in metastatic
    Bone Disease
  • Bone Metastases
    and SREs
  • Prostate
    Cancer
  • Breast
    Cancer
  • Osteoblastic versus osteolytic bone metastases
  • RANK Ligand drives a "vicious cycle" of metastatic bone destruction and tumour growth
  • Get to know the KEY PLAYERS in the vicious
    cycle of metastatic bone destruction.
  • Vicious Cycle
  • Click to Play

The role of RANK Ligand in metastatic bone disease.

Osteoblastic versus osteolytic bone metastases

Bone metastases are often characterized by their radiographic appearance as either osteolytic, osteoblastic, or mixed.1,2

Most patients with breast cancer have predominantly mixed or osteolytic lesions.1,2 In contrast, patients with prostate cancer are often found to have predominantly osteoblastic lesions. However, regardless of appearance, there is significant osteolytic activity. In fact, osteolytic activity in these lesions often is comparable with, if not higher than, that typically seen in breast cancer and multiple myeloma. Such activity has been demonstrated by markedly elevated biochemical markers of bone resorption in the serum and urine of such patients.1,3,4 Only in multiple myeloma do purely lytic bone lesions develop.1,2

AMGEN Oncology

This site is intended for use by Canadian Healthcare Professionals only

© 2010 Amgen. All rights reserved. Contact us | Site map | Privacy & terms

Member R&D, PAAB